295530

Data Analytics Stocks Q2 Earnings: Alteryx (NYSE:AYX) Best of the Bunch


Kayode Omotosho /
2022/10/18 3:34 am EDT

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to other peers in the same sector. Today we are looking at Alteryx (NYSE:AYX), and the best and worst performers in the data analytics group.

Organizations generate a lot of data that is stored in silos, often in incompatible formats, making it slow and costly to extract actionable insights, which in turn drives demand for modern cloud-based data analysis platforms that can efficiently analyze the silo-ed data.

The 5 data analytics stocks we track reported a mixed Q2; on average, revenues beat analyst consensus estimates by 3.55%, while on average next quarter revenue guidance was 1.88% under consensus. Tech stocks have been under pressure as inflation makes their long-dated profits less valuable and data analytics stocks have not been spared, with share prices down 27.3% since the previous earnings results, on average.

Best Q2: Alteryx (NYSE:AYX)

Initially created as a way to organise census data for the government, Alteryx (NYSE:AYX) provides software that helps companies automate and analyse their internal data processes.

Alteryx reported revenues of $180.6 million, up 50.4% year on year, beating analyst expectations by 12.2%. It was an incredible quarter for the company, with an impressive beat of analyst estimates and a very optimistic guidance for the next quarter.

"Alteryx delivered an outstanding quarter with ARR growth of 33% year-over-year, driven by our continued success with large enterprise organizations," said Mark Anderson, CEO of Alteryx, Inc.

Alteryx Total Revenue

Alteryx achieved the strongest analyst estimates beat, fastest revenue growth, and highest full year guidance raise of the whole group. The company added 101 customers to a total of 8,296. The stock is down 3.23% since the results and currently trades at $49.00.

We think Alteryx is a good business, but is it a buy today? Read our full report here, it's free.

Amplitude (NASDAQ:AMPL)

Born out of a failed voice recognition startup by founder Spenser Skates, Amplitude (NASDAQ:AMPL) is data analytics software helping companies improve and optimize their digital products.

Amplitude reported revenues of $58.1 million, up 48% year on year, beating analyst expectations by 5.34%. It was a strong quarter for the company, with an exceptional revenue growth and a solid beat of analyst estimates.

Amplitude Total Revenue

The stock is down 8.35% since the results and currently trades at $14.81.

Is now the time to buy Amplitude? Access our full analysis of the earnings results here, it's free.

Weakest Q2: Domo (NASDAQ:DOMO)

Founded by Josh James after selling his former business Omniture to Adobe, Domo (NASDAQ:DOMO) provides business intelligence software that allows managers to access and visualize critical business metrics in real-time, using their smartphones.

Domo reported revenues of $75.5 million, up 20.2% year on year, missing analyst expectations by 1.13%. It was a weak quarter for the company, with revenue guidance for both the next quarter and the full year missing analysts' expectations.

Domo had the weakest performance against analyst estimates in the group. The stock is down 44.7% since the results and currently trades at $15.79.

Read our full analysis of Domo's results here.

Health Catalyst (NASDAQ:HCAT)

Founded by healthcare professionals Tom Burton and Steve Barlow in 2008, Health Catalyst (NASDAQ:HCAT) provides data and analytics technology to healthcare organizations, enabling them to improve care and lower costs.

Health Catalyst reported revenues of $70.6 million, up 18.4% year on year, beating analyst expectations by 1.08%. It was a weak quarter for the company, with revenue guidance for both the next quarter and the full year missing analysts' expectations.

Health Catalyst had the slowest revenue growth and weakest full year guidance update among the peers. The stock is down 50.4% since the results and currently trades at $9.01.

Read our full, actionable report on Health Catalyst here, it's free.

Palantir (NYSE:PLTR)

Started by Peter Thiel after seeing US defense agencies struggle in the aftermath of the 2001 terrorist attacks, Palantir (NYSE:PLTR) offers software as a service platform that helps government agencies and large enterprises use data to make better decisions.

Palantir reported revenues of $473 million, up 25.9% year on year, in line with analyst expectations. It was a weak quarter for the company, with revenue guidance for the next quarter missing analysts' expectations.

The stock is down 29.9% since the results and currently trades at $8.01.

Read our full, actionable report on Palantir here, it's free.

The author has no position in any of the stocks mentioned